Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Net Income towards Common Stockholders (2016 - 2025)

Seres Therapeutics' Net Income towards Common Stockholders history spans 11 years, with the latest figure at $32.7 million for Q1 2025.

  • For Q1 2025, Net Income towards Common Stockholders rose 181.43% year-over-year to $32.7 million; the TTM value through Sep 2025 reached $32.7 million, up 156.48%, while the annual FY2024 figure was $125.9 million, 64.79% up from the prior year.
  • Net Income towards Common Stockholders for Q1 2025 was $32.7 million at Seres Therapeutics, down from $139.8 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $139.8 million in Q3 2024 and bottomed at -$124.7 million in Q4 2023.
  • The 5-year median for Net Income towards Common Stockholders is -$44.1 million (2021), against an average of -$23.2 million.
  • The largest annual shift saw Net Income towards Common Stockholders tumbled 187.96% in 2022 before it soared 2144.32% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$49.7 million in 2021, then plummeted by 38.46% to -$68.8 million in 2022, then tumbled by 81.22% to -$124.7 million in 2023, then skyrocketed by 212.15% to $139.8 million in 2024, then tumbled by 76.62% to $32.7 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Net Income towards Common Stockholders are $32.7 million (Q1 2025), $139.8 million (Q3 2024), and -$32.9 million (Q2 2024).